Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients

Ashokkumar Jain, M. Orloff, P. Abt, R. Kashyap, R. Mohanka, K. Lansing, J. Romano, A. Bozorgzadeh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction. Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation in the United States. Recurrence of HCV infection in these recipients is almost uniform. The currently available antiviral treatment is known to cause significant side effects, and the rate of sustained viral response is low. There is still controversy about whether such patients should undergo subsequent transplantations for HCV disease. This study compared outcomes for hepatic retransplantation performed in HCV(+) and HCV(-) recipients at a single center. Patients and methods. From December 1994 through November 2003, 68 patients at our institution received a second liver allograft. Nineteen of the recipients were HCV(-) (group A) and 49 were HCV(-) (group B). All patients were followed until January 2004. The mean follow-up time after initial retransplantation was 37 ± 29 months. Patient and graft survival for the two groups were compared. Results. Seven recipients in group A (36.8%) and 22 recipients in group B (44.9%) died during follow-up. The actuarial 3-year patient survival after initial retransplantation for groups A and B were 61.7% and 51.6%, respectively. Nine patients required a second retransplantation, 3 (15.8%) in group A and 6 (12.2%) in group B. The actuarial 3-year graft survival from initial retransplantation for groups A and B were 56.3% and 45.7%, respectively. Conclusion. We observed slightly better patient and graft survivals at 3 years from initial retransplantation in HCV(+) recipients compared to HCV(-) recipients. This may be due to younger donor age and better selection of HCV(+) recipients in this series.

Original languageEnglish (US)
Pages (from-to)3159-3161
Number of pages3
JournalTransplantation Proceedings
Volume37
Issue number7
DOIs
StatePublished - Sep 1 2005

Fingerprint

Hepacivirus
Survival
Liver
Graft Survival
Virus Diseases
Liver Transplantation
Antiviral Agents
Allografts
Liver Diseases
Transplantation
Outcome Assessment (Health Care)
Tissue Donors
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Jain, Ashokkumar ; Orloff, M. ; Abt, P. ; Kashyap, R. ; Mohanka, R. ; Lansing, K. ; Romano, J. ; Bozorgzadeh, A. / Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients. In: Transplantation Proceedings. 2005 ; Vol. 37, No. 7. pp. 3159-3161.
@article{291ff76bba0a4105be0035d8f59678b4,
title = "Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients",
abstract = "Introduction. Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation in the United States. Recurrence of HCV infection in these recipients is almost uniform. The currently available antiviral treatment is known to cause significant side effects, and the rate of sustained viral response is low. There is still controversy about whether such patients should undergo subsequent transplantations for HCV disease. This study compared outcomes for hepatic retransplantation performed in HCV(+) and HCV(-) recipients at a single center. Patients and methods. From December 1994 through November 2003, 68 patients at our institution received a second liver allograft. Nineteen of the recipients were HCV(-) (group A) and 49 were HCV(-) (group B). All patients were followed until January 2004. The mean follow-up time after initial retransplantation was 37 ± 29 months. Patient and graft survival for the two groups were compared. Results. Seven recipients in group A (36.8{\%}) and 22 recipients in group B (44.9{\%}) died during follow-up. The actuarial 3-year patient survival after initial retransplantation for groups A and B were 61.7{\%} and 51.6{\%}, respectively. Nine patients required a second retransplantation, 3 (15.8{\%}) in group A and 6 (12.2{\%}) in group B. The actuarial 3-year graft survival from initial retransplantation for groups A and B were 56.3{\%} and 45.7{\%}, respectively. Conclusion. We observed slightly better patient and graft survivals at 3 years from initial retransplantation in HCV(+) recipients compared to HCV(-) recipients. This may be due to younger donor age and better selection of HCV(+) recipients in this series.",
author = "Ashokkumar Jain and M. Orloff and P. Abt and R. Kashyap and R. Mohanka and K. Lansing and J. Romano and A. Bozorgzadeh",
year = "2005",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2005.07.048",
language = "English (US)",
volume = "37",
pages = "3159--3161",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

Jain, A, Orloff, M, Abt, P, Kashyap, R, Mohanka, R, Lansing, K, Romano, J & Bozorgzadeh, A 2005, 'Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients', Transplantation Proceedings, vol. 37, no. 7, pp. 3159-3161. https://doi.org/10.1016/j.transproceed.2005.07.048

Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients. / Jain, Ashokkumar; Orloff, M.; Abt, P.; Kashyap, R.; Mohanka, R.; Lansing, K.; Romano, J.; Bozorgzadeh, A.

In: Transplantation Proceedings, Vol. 37, No. 7, 01.09.2005, p. 3159-3161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients

AU - Jain, Ashokkumar

AU - Orloff, M.

AU - Abt, P.

AU - Kashyap, R.

AU - Mohanka, R.

AU - Lansing, K.

AU - Romano, J.

AU - Bozorgzadeh, A.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Introduction. Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation in the United States. Recurrence of HCV infection in these recipients is almost uniform. The currently available antiviral treatment is known to cause significant side effects, and the rate of sustained viral response is low. There is still controversy about whether such patients should undergo subsequent transplantations for HCV disease. This study compared outcomes for hepatic retransplantation performed in HCV(+) and HCV(-) recipients at a single center. Patients and methods. From December 1994 through November 2003, 68 patients at our institution received a second liver allograft. Nineteen of the recipients were HCV(-) (group A) and 49 were HCV(-) (group B). All patients were followed until January 2004. The mean follow-up time after initial retransplantation was 37 ± 29 months. Patient and graft survival for the two groups were compared. Results. Seven recipients in group A (36.8%) and 22 recipients in group B (44.9%) died during follow-up. The actuarial 3-year patient survival after initial retransplantation for groups A and B were 61.7% and 51.6%, respectively. Nine patients required a second retransplantation, 3 (15.8%) in group A and 6 (12.2%) in group B. The actuarial 3-year graft survival from initial retransplantation for groups A and B were 56.3% and 45.7%, respectively. Conclusion. We observed slightly better patient and graft survivals at 3 years from initial retransplantation in HCV(+) recipients compared to HCV(-) recipients. This may be due to younger donor age and better selection of HCV(+) recipients in this series.

AB - Introduction. Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation in the United States. Recurrence of HCV infection in these recipients is almost uniform. The currently available antiviral treatment is known to cause significant side effects, and the rate of sustained viral response is low. There is still controversy about whether such patients should undergo subsequent transplantations for HCV disease. This study compared outcomes for hepatic retransplantation performed in HCV(+) and HCV(-) recipients at a single center. Patients and methods. From December 1994 through November 2003, 68 patients at our institution received a second liver allograft. Nineteen of the recipients were HCV(-) (group A) and 49 were HCV(-) (group B). All patients were followed until January 2004. The mean follow-up time after initial retransplantation was 37 ± 29 months. Patient and graft survival for the two groups were compared. Results. Seven recipients in group A (36.8%) and 22 recipients in group B (44.9%) died during follow-up. The actuarial 3-year patient survival after initial retransplantation for groups A and B were 61.7% and 51.6%, respectively. Nine patients required a second retransplantation, 3 (15.8%) in group A and 6 (12.2%) in group B. The actuarial 3-year graft survival from initial retransplantation for groups A and B were 56.3% and 45.7%, respectively. Conclusion. We observed slightly better patient and graft survivals at 3 years from initial retransplantation in HCV(+) recipients compared to HCV(-) recipients. This may be due to younger donor age and better selection of HCV(+) recipients in this series.

UR - http://www.scopus.com/inward/record.url?scp=26444497979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444497979&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.07.048

DO - 10.1016/j.transproceed.2005.07.048

M3 - Article

C2 - 16213336

AN - SCOPUS:26444497979

VL - 37

SP - 3159

EP - 3161

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -